跳至主要内容
临床试验/NCT03903653
NCT03903653撤回2 期

Effects of Chemodenervation (Botulinum Toxin A) and Serial Casting vs Botulinum Toxin A and Without Serial Casting in Lower Limb Spasticity Following ABI

Hamilton Health Sciences Corporation0 个研究点开始时间: 2019年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
主要终点
Passive ankle dorsiflexion >10 degrees

研究概览

简要总结

Effects of Chemodenervation (Botulinum Toxin A) and Serial Casting vs Botulinum Toxin A and without serial casting in Lower Limb Spasticity following ABI.

详细描述

The investigators will be studying the effects of Chemodenervation (Botulinum Toxin A) and Serial Casting vs Botulinum Toxin A and without serial casting in Lower Limb Spasticity following ABI.

patients are randomly divided into two groups: group 1 will undergo botox injection with weekly serial casting group 2 will undergo botox injection with physiotherapy The primary outcome is the effects of the proposed treatment with respect to passive dorsiflexion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Chemodenervation + Serial Casting

Active Comparator

in this group a total of 10 patients will undergo Botulinum Toxin A injection and weekly serial casting Intervention = Weekly Serial Casting AND Botulinum Toxin A injection (350-400 units per treated limb)

干预措施: Botulinum toxin type A (Drug)

Chemodenervation + Serial Casting

Active Comparator

in this group a total of 10 patients will undergo Botulinum Toxin A injection and weekly serial casting Intervention = Weekly Serial Casting AND Botulinum Toxin A injection (350-400 units per treated limb)

干预措施: Serial Casting (Device)

Chemodenervation without serial casting

Active Comparator

in this group a total of 10 patients will undergo Botulinum Toxin A injection. Intervention = Botulinum Toxin A injection (350-400 units per treated limb) alone.

干预措施: Botulinum toxin type A (Drug)

结局指标

主要结局

Passive ankle dorsiflexion >10 degrees

时间窗: 4-6 weeks

we are measuring passive ankle range of motion with respect to dorsiflexion greater than 10 degrees

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ali Fateh

Resident - Dept of Physical Medicine and Rehabilitation

Hamilton Health Sciences Corporation

相似试验

尚未招募
3 期
Effect of Botulinum A toxin versus anticholinergic on clinical symptoms of patients with overactive bladder
IRCT20120215009014N488Hamedan University of Medical Sciences42
进行中(未招募)
不适用
Effect of Botulinum Toxin A Injections and Specific Intensive Rehabilitation Therapy in Children with Hemiparetic Cerebral Palsy on Upper Limb Functions and Skills - BoBiVa (Botuline toxine Bimanuele Vaardigheden)Study design: a factorial design with four study groups in which btA alone, intensive rehabilitation therapy aimed at improving bimanual skills alone, a combination of these two and continuing the regular therapy program will be compared to each other.Study population: children with CP, spastic hemiparesis, aged 2.5 – 12 years.
EUCTR2006-002175-40-NL60
已完成
3 期
Effect of Botulinum Toxin A Injections and Specific Intensive Rehabilitation Therapy in Children with Hemiparetic Cerebral Palsy on Upper Limb Functions and Skillscongenital hemiparesisSpastic hemiparetic cerebral palsy10010335
NL-OMON30186Hoensbroek Revalidatiecentrum (HRC)60
尚未招募
不适用
Botulinum toxin type A injections in stiff knee gait.In the Netherlands live about 18.000 Cerebro Vascular Accident (CVA)-patients which discover problems with walking caused by insufficient footclearance. Causes of problems with the footclearance during the swing phase of gait are a combination of diminished dorsal flexion of the ankle, knee flexion and hip flexion. A diminished knee flexion during swing is defined a stiff knee gait. A stiff knee gait is often caused by an overactivity of the m. rectus femoris. Keywords: stroke, stiff knee gait
NL-OMON29171Roessingh Research and DevelopmentRoessinghsbleekweg 337577 AH Enschede26
已完成
不适用
Assessment of efficacy of Botulinium toxin A for treatment of keloidkeloid scar.Hypertrophic scar
IRCT2014071918533N1euronox company(Tehran reseller)20